4599 Stock Overview
A biotechnology company, develops regeneration medicines for the treatment of intractable diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
StemRIM Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥373.00 |
| 52 Week High | JP¥1,022.00 |
| 52 Week Low | JP¥366.00 |
| Beta | 1.42 |
| 11 Month Change | -17.48% |
| 3 Month Change | -26.57% |
| 1 Year Change | -63.29% |
| 33 Year Change | -54.29% |
| 5 Year Change | n/a |
| Change since IPO | -60.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4599 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -8.6% | 0.06% | -0.6% |
| 1Y | -63.3% | -18.7% | 17.8% |
Return vs Industry: 4599 underperformed the JP Biotechs industry which returned -18.7% over the past year.
Return vs Market: 4599 underperformed the JP Market which returned 17.8% over the past year.
Price Volatility
| 4599 volatility | |
|---|---|
| 4599 Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in JP Market | 7.4% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4599's share price has been volatile over the past 3 months.
Volatility Over Time: 4599's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 45 | Masatsune Okajima | www.stemrim.com |
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy.
StemRIM Fundamentals Summary
| 4599 fundamental statistics | |
|---|---|
| Market cap | JP¥22.95b |
| Earnings (TTM) | -JP¥2.13b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.8x
P/E RatioIs 4599 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4599 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥2.13b |
| Earnings | -JP¥2.13b |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -34.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4599 perform over the long term?
See historical performance and comparison